Unlocking the Economic Potential of Dementia Research: A Call for Increased Investment

By HEOR Staff Writer

July 17, 2023

UK government funding for dementia research has declined from its peak in 2018-2019. Despite this, the field shows high potential for research in the coming years. By 2040, over 1.2 million people in the UK are expected to have dementia, a 30% increase from 2022. The economic benefits of dementia research can be measured through an economic impact assessment (EIA), which considers various dimensions of dementia research. The report also highlights the significant impact of COVID-19 on people with dementia.

  • Dementia research in 2019/20 generated 7,353 full-time equivalent (FTE) jobs and contributed over £529 million in gross value added (GVA) to the UK economy.
  • Directly, dementia research supported 2,607 FTE jobs, including 2,059 research/scientific and technical roles and 548 administrative roles, contributing over £276 million in GVA.
  • Indirectly, dementia research supported and created 4,746 FTE jobs, contributing over £252 million in GVA.
  • Full-time salaries in dementia R&D and administration are, on average, 41% and 24.5% higher respectively than the average salary across all jobs in a region.

The risk of developing dementia or becoming an informal carer for a person with dementia is high. The study found that every £1 invested in dementia research generated £2.59 of economic benefit in the UK during 2019/20, and this is expected to increase to £2.91 on average in the next 20 years. Thus, increased investment in dementia research could improve the lives of those affected by dementia and create long-term economic growth in the UK.

Reference url

Recent Posts

Johnson & Johnson’s Medicine Access Agreement: Paving the Way for Cost Reduction and U...

By HEOR Staff Writer

January 12, 2026

Johnson & Johnson has reached a landmark medicine access agreement with the U.S. government, aimed at broadening access to its pharmaceutical products and slashing costs for millions of American patients. Under this voluntary arrangement during the Trump Administration, the company's medicine...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
Confirmation of Adjusted Cost-Effectiveness Thresholds for NHS Medicines Evaluations The UK's National Institute for Health and Care Excellence (
Driving Economic Transformation through Brain Health Investment in Africa

By João L. Carapinha

January 9, 2026

The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...